Showing 1 – 2 of 2
Relevance | Newest | Oldest |
  • Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy

    Abstract Full Text
    online first
    JAMA Oncol. 2024; 10.1001/jamaoncol.2024.0578

    This cohort study examines oncological outcomes after sentinel lymph node biopsy with dual-tracer mapping or targeted axillary dissection.

  • Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer

    Abstract Full Text
    JAMA Surg. 2023; 158(8):807-815. 10.1001/jamasurg.2023.1772

    This cohort study assesses 3-year clinical outcomes in patients with node-positive breast cancer who underwent targeted axillary dissection alone or in combination with axillary lymph node dissection.